Skip Navigation

Cardiovascular Research 1997 34(1):69-72; doi:10.1016/S0008-6363(97)00014-X
© 1997 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Horie, M.
Right arrow Articles by Sasayama, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horie, M.
Right arrow Articles by Sasayama, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs

Minoru Horiea,*, Ayako Ishida-Takahashia, Tomohiko Aia, Toshihisa Nishimotoa, Yoshiyuki Tsuurab, Hitoshi Ishidab, Yutaka Seinob and Shigetake Sasayamaa

aDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-01, Japan
bDepartment of Metabolism and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto 606-01, Japan

* Corresponding author. Division of Cardiac Electrophysiology, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-01, Japan. Tel. +81 75 751-3196; Fax +81 75 752-0856; E-mail: horie@kuhp.kyoto-u.ac.jp

Cardiovascular drugs such as antiarrhythmic agents with Vaughan Williams class Ia action have been found to induce a sporadic hypoglycemia. Recent investigation has revealed that these drugs induce insulin secretion from pancreatic β-cells by inhibiting ATP-sensitive K+ (KATP) channels in a manner similar to sulfonylurea drugs. The mechanism underlying block of KATP channels by antiarrhythmic drugs was different, however, from that of sulfonylureas: firstly, because binding of radioactive glibenclamide could not be inhibited by unlabelled antiarrhythmic agents, and vice versa; secondly, because the two compounds differ in the kinetics and sidedness of drug action—antiarrhythmic drugs act on the channel from the inner surface of the cell membrane, whereas glibenclamide binds through the intramembrane pathway; finally, it was shown that functional KATP channels in β-cells are composed of two distinct molecules—a sulfonylurea receptor (SUR) and a channel pore-forming subunit, an inwardly-rectifying K channel with two transmembrane regions (Kir6.2). Antiarrhythmic drugs reversibly inhibit the K+ conductance displayed by the Kir6.1 (a putative KATP channel clone)-transfected NIH3T3 cells. Therefore they appear to interact directly with the pore-forming subunit, thereby inhibiting KATP channel currents and exerting an insulinotrophic effect.

KEYWORDS Antiarrhythmic drugs; Sulfonylureas; Potassium channel, ATP-sensitive


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
C. E. Schotborgh and A. A.M. Wilde
ATP-Sensitive Potassium Channel Openers and Blockers in the Cardiovascular System: Physiology, Pharmacology, and Clinical Effects
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 243 - 255.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.